Bufalin serves as a pharmaceutic that mitigates drug resistance
Intrinsic or acquired drug resistance of tumor cells is the main cause of tumor chemotherapy failure and tumor-related death. Bufalin (BF) is the main active monomer component extracted from the Traditional Chinese Medicine Toad venom (secretions of glands behind the ears and epidermis of bufo gargarizans and Bufo Melanostictus Schneider). It is a cardiotonic steroid with broad-spectrum anti-cancer effects and has been widely used against various malignant tumors in clinical practice. Pharmacological studies also found that BF has the effect of reversing drug resistance, which provides a new perspective for the application of Traditional Chinese Medicine as a chemosensitizer in cancer therapy. This article provides an extensive search and summary of published research on mitigating drug resistance to BF and reviews its potential mechanisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 55(2023), 3 vom: 28. Aug., Seite 195-204 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miao, Linxuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bufalin |
|---|
| Anmerkungen: |
Date Completed 28.07.2023 Date Revised 30.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03602532.2023.2206065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356179109 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356179109 | ||
| 003 | DE-627 | ||
| 005 | 20231226065919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2023.2206065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356179109 | ||
| 035 | |a (NLM)37114332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miao, Linxuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bufalin serves as a pharmaceutic that mitigates drug resistance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2023 | ||
| 500 | |a Date Revised 30.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Intrinsic or acquired drug resistance of tumor cells is the main cause of tumor chemotherapy failure and tumor-related death. Bufalin (BF) is the main active monomer component extracted from the Traditional Chinese Medicine Toad venom (secretions of glands behind the ears and epidermis of bufo gargarizans and Bufo Melanostictus Schneider). It is a cardiotonic steroid with broad-spectrum anti-cancer effects and has been widely used against various malignant tumors in clinical practice. Pharmacological studies also found that BF has the effect of reversing drug resistance, which provides a new perspective for the application of Traditional Chinese Medicine as a chemosensitizer in cancer therapy. This article provides an extensive search and summary of published research on mitigating drug resistance to BF and reviews its potential mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Bufalin | |
| 650 | 4 | |a cinobufacini | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a review | |
| 650 | 4 | |a tumor | |
| 650 | 7 | |a bufalin |2 NLM | |
| 650 | 7 | |a U549S98QLW |2 NLM | |
| 650 | 7 | |a Bufanolides |2 NLM | |
| 700 | 1 | |a Liu, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Nasra Mohamoud |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Xiaonan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d 1973 |g 55(2023), 3 vom: 28. Aug., Seite 195-204 |w (DE-627)NLM000049530 |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g number:3 |g day:28 |g month:08 |g pages:195-204 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03602532.2023.2206065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |e 3 |b 28 |c 08 |h 195-204 | ||